publication date: Mar. 10, 2017
Issue 10 - Mar. 10, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • DePinho resigns as MD Anderson president, acknowledges shortcomings as administrator

    Ronald DePinho announced on March 8 that he will be stepping down as president of MD Anderson Cancer Center.

    DePinho’s five-and-a-half years at the helm of the world’s largest cancer center were marked by unprecedented turbulence, questions of conflicts of interest, and unhappiness on the part of the faculty.

  • House Republicans publish legislation for replacing Obamacare with Trumpcare

    The House Republicans on March 6 published the Obamacare repeal bill, touching off predictable tidal waves of recriminations, with Democrats stating that the bill would “rip healthcare away from millions of Americans, ration care for working families and seniors, and put insurance companies back in charge of healthcare decisions”

  • Note to international travelers: U.S. customs can take your laptop and ask for passwords

    As spring meetings get going, many cancer organizations are offering what amounts to packing tips, suggesting that some electronic devices are best left at home.

  • In Brief

    • Lynch steps in as CSO at Bristol-Myers Squibb
    • Pharma companies collaborate in NCCN’s multi-industry project
    • NCCN “Just Bag It!” campaign shoots for 100 new adopters by end of conference
    • Targeted Anticancer Therapies Congress becomes an annual ESMO Event
    • ASCO and ONS launch collaboration to advance engagement in CancerLinQ
    • Siteman Cancer Center launches network with affiliation of Boone hospital
  • Drugs and Targets

    • NICE recommends Vectibix for previously untreated metastatic colorectal cancer
    • EnGeneIC receives Orphan designation for its technology in glioblastoma multiforme
    • German Community of Gynecological Oncology acknowledges MammaPrint as having Level 1A clinical evidence 

Copyright (c) 2017 The Cancer Letter Inc.